HACKENSACK, N.J. & AACHEN, Germany--(BUSINESS WIRE)--CircuLite™, Inc. today announced that the Company has advanced its Synergy™ Pocket Circulatory Assist Device clinical program into a 20-patient trial designed to lead to CE Mark approval in the European Union for long-term implantation of Synergy in heart failure patients. This announcement follows successful completion of a first-in-man pilot study of Synergy in four patients. Synergy is a micro implantable blood pump, the size of a AA battery, that can be implanted superficially in a “pacemaker-like” pocket. The device is designed to provide long-term, partial circulatory support in patients with chronic heart failure.
